Do Non-Prescription Products Help in Managing Androgenic Alopecia?

IF 1.4 Q3 DERMATOLOGY
Skin Appendage Disorders Pub Date : 2025-06-01 Epub Date: 2024-12-06 DOI:10.1159/000542880
Aditya K Gupta, Honglin Wang, Tong Wang, Mesbah Talukder
{"title":"Do Non-Prescription Products Help in Managing Androgenic Alopecia?","authors":"Aditya K Gupta, Honglin Wang, Tong Wang, Mesbah Talukder","doi":"10.1159/000542880","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Androgenetic alopecia (AGA) is the most common cause of hair loss. Currently, approved medications for AGA are topical minoxidil and oral finasteride, both of which are prescription medications which may cause side effects. Non-prescription products such as herbal extracts and over-the-counter medications have limited evidence regarding safety and efficacy; however, they may be an alternative for patients unable or unwilling to use prescription medication.</p><p><strong>Summary: </strong>This article reviews investigator-blinded, controlled clinical trials assessing the efficacy of non-prescription monotherapies in treating AGA. A total of 13 studies were included using procyanidin, cetirizine, caffeine, <i>Oryza sativa</i> bran, pumpkin seed oil, rosemary oil, saw palmetto, and watercress. The available data demonstrate considerable improvements in one or more parameters: total hair density, terminal hair density and hair diameter. Procyanidin and cetirizine were investigated in more investigator-blinded, randomized controlled trials than other agents. Minimal adverse events were observed; however, more robust clinical trial and long-term safety and efficacy data are warranted.</p><p><strong>Key message: </strong>Additional investigations through the conduct of high quality randomized, controlled trials with larger numbers of patients will help determine the effectiveness and safety of this class of compounds, either as monotherapy or as an addition to current pharmacological interventions.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":"11 3","pages":"270-281"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12136554/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin Appendage Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000542880","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Androgenetic alopecia (AGA) is the most common cause of hair loss. Currently, approved medications for AGA are topical minoxidil and oral finasteride, both of which are prescription medications which may cause side effects. Non-prescription products such as herbal extracts and over-the-counter medications have limited evidence regarding safety and efficacy; however, they may be an alternative for patients unable or unwilling to use prescription medication.

Summary: This article reviews investigator-blinded, controlled clinical trials assessing the efficacy of non-prescription monotherapies in treating AGA. A total of 13 studies were included using procyanidin, cetirizine, caffeine, Oryza sativa bran, pumpkin seed oil, rosemary oil, saw palmetto, and watercress. The available data demonstrate considerable improvements in one or more parameters: total hair density, terminal hair density and hair diameter. Procyanidin and cetirizine were investigated in more investigator-blinded, randomized controlled trials than other agents. Minimal adverse events were observed; however, more robust clinical trial and long-term safety and efficacy data are warranted.

Key message: Additional investigations through the conduct of high quality randomized, controlled trials with larger numbers of patients will help determine the effectiveness and safety of this class of compounds, either as monotherapy or as an addition to current pharmacological interventions.

非处方产品有助于治疗雄激素性脱发吗?
背景:雄激素性脱发(AGA)是最常见的脱发原因。目前,批准的治疗AGA的药物是外用米诺地尔和口服非那雄胺,这两种药物都是可能导致副作用的处方药。草药提取物和非处方药等非处方产品在安全性和有效性方面的证据有限;然而,对于不能或不愿使用处方药的患者,它们可能是一种选择。摘要:本文回顾了研究者盲法对照临床试验,评估非处方单一疗法治疗AGA的疗效。总共有13项研究使用了原花青素、西替利嗪、咖啡因、水稻麸皮、南瓜籽油、迷迭香油、锯棕榈和豆瓣菜。现有数据表明,在一个或多个参数上有相当大的改善:总发密度、终末发密度和发径。与其他药物相比,原花青素和西替利嗪在更多的研究者盲法随机对照试验中被研究。观察到最小的不良事件;然而,需要更可靠的临床试验和长期安全性和有效性数据。关键信息:通过对大量患者进行高质量随机对照试验的进一步调查,将有助于确定这类化合物的有效性和安全性,无论是作为单一疗法还是作为当前药物干预的补充。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
10.00%
发文量
69
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信